AbbVie Inc (ABBV)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$222.50

Buy

$224.34

arrow-down$-0.66 (-0.29%)

Prices updated at 13 Dec 2025, 00:42 EST

Prices minimum 15 mins delay

Prices in USD

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Robert A. Michael

CEO

Mr. Robert A. Michael

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

55,000

Head office

1 North Waukegan Road

North Chicago

United States

60064-6400

+1 847 932-7900

liz.shea@abbvie.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Thomas J. Falk Independent Director	-
Ms. Roxanne S. Austin Lead Independent Director	0.16m
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer	1.61m
Mr. Kevin K. Buckbee Senior Vice President, Controller and Principal Accounting Officer	-
Mr. Frederick H. Waddell Independent Director	0.14m
Ms. Rebecca B. Roberts Independent Director	0.12m
Dr. Robert J. Alpern,M.D. Independent Director	0.12m
Mr. Thomas C. Freyman Independent Director	0.15m
Mr. Edward J. Rapp Independent Director	0.14m
Mr. Brett J. Hart Independent Director	0.15m
Mr. Timothy J. Richmond Executive Vice President and Chief Human Resources Officer	1.02m
Dr. Azita Saleki-Gerhardt, B.S.,M.S.,PhD Executive Vice President and Chief Operations Officer	1.02m
Mr. William H.L. Burnside Independent Director	0.13m
Ms. Melody B. Meyer Independent Director	0.14m
Mr. Jeffrey Ryan Stewart Executive Vice President and Chief Commercial Officer	1.28m
Dr. Nicholas J. Donoghoe, M.D. Executive Vice President, Chief Business and Strategy Officer	-
Mr. Scott Reents Executive Vice President and Chief Financial Officer	1.07m
Ms. Jennifer L. Davis Independent Director	0.12m
Mr. Perry C. Siatis Executive Vice President, General Counsel and Secretary	-
Dr. Susan E. Quaggin, M.D. Independent Director	0.12m
Dr. Roopal Thakkar, M.D. Executive Vice President, Research and Development and Chief Scientific Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	177,298,707
BlackRock Inc	145,977,089
JPMorgan Chase & Co	113,069,632
State Street Corp	79,821,657
Vanguard Investments Australia Ltd	56,500,905

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
24 Sep 2024	-
05 Aug 2024	-
17 Jul 2024	-
17 Jul 2024	-
17 Jul 2024	-
17 Jul 2024	-
17 Jul 2024	-
17 Jul 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.